Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
ПРЕСС-РЕЛИЗ
ПРЕСС-РЕЛИЗ
ПРЕСС-РЕЛИЗ. Онкология. 2006; 3: 7-8.
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Harries M, Smith I. The development and clinical use of trastuzumab (Herceptin). Endocr Relat Cancer 2002; 9: 75–85.
2. Piccart-Gebhart M, Procter M, Leyland-Jones B et al. A Randomized Trial of Trastuzumab Following Adjuvant Chemotherapy in Women with HER2 Positive Breast Cancer. New Engl J Med 2005; 353: 16.
3. NCCTG N9831 (US), NSABP B-31 (US), BCIRG 006 (international).
4. Romond E, Perez E et al. Trastuzumab plus Adjuvant Chemotherapy for Operable HER2 Positive Breast Cancer. New England J Med 2005; 353: 16.
5. World Health Organization, 2000.
6. Extra JM, Cognetti F, Maraninchi D et al. Long-term survival demonstrated with trastuzumab plus docetaxel: 24-month data from a randomised trial (M77001) in HER2-positive metastatic breast cancer. Abstract #555, American Society for Clinical Oncology (ASCO) Annual Meeting 2005.
2. Piccart-Gebhart M, Procter M, Leyland-Jones B et al. A Randomized Trial of Trastuzumab Following Adjuvant Chemotherapy in Women with HER2 Positive Breast Cancer. New Engl J Med 2005; 353: 16.
3. NCCTG N9831 (US), NSABP B-31 (US), BCIRG 006 (international).
4. Romond E, Perez E et al. Trastuzumab plus Adjuvant Chemotherapy for Operable HER2 Positive Breast Cancer. New England J Med 2005; 353: 16.
5. World Health Organization, 2000.
6. Extra JM, Cognetti F, Maraninchi D et al. Long-term survival demonstrated with trastuzumab plus docetaxel: 24-month data from a randomised trial (M77001) in HER2-positive metastatic breast cancer. Abstract #555, American Society for Clinical Oncology (ASCO) Annual Meeting 2005.
Авторы
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.